<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=us-ascii"><meta name=Generator content="Microsoft Word 14 (filtered medium)"><style><!--
/* Font Definitions */
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri","sans-serif";}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
{mso-style-priority:99;
mso-style-link:"Plain Text Char";
margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri","sans-serif";}
span.PlainTextChar
{mso-style-name:"Plain Text Char";
mso-style-priority:99;
mso-style-link:"Plain Text";
font-family:"Calibri","sans-serif";}
.MsoChpDefault
{mso-style-type:export-only;
font-family:"Calibri","sans-serif";}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-US link=blue vlink=purple><div class=WordSection1><p class=MsoPlainText>>... On Behalf Of spike<br>Subject: Re: [ExI] good bexarotene article</p><p class=MsoPlainText><o:p> </o:p></p><p class=MsoPlainText><o:p> </o:p></p><p class=MsoPlainText>>... What I am doing now is trying to find out if there have been other medications which have reduced amyloid plaques in mouse brains, then been tested on humans and found not effective in treatment of humans. If so, that will be a clue. A discouraging one, but a clue... spike<o:p></o:p></p><p class=MsoPlainText><span style='color:black'><o:p> </o:p></span></p><p class=MsoPlainText><span style='color:black'>Woohooo, NO! There has not been any class of drugs which do what bexarotene appears to do to Alz mice. Here's the money quote:<o:p></o:p></span></p><p class=MsoPlainText><span style='color:black'><o:p> </o:p></span></p><p class=MsoNormal><span style='color:black'>"This is an unprecedented finding," says Paige Cramer, PhD candidate at Case Western Reserve School of Medicine and first author of the study. "Previously, the best existing treatment for Alzheimer's disease in mice required several months to reduce plaque in the brain."<o:p></o:p></span></p><p class=MsoPlainText><span style='color:black'><o:p> </o:p></span></p><p class=MsoPlainText><span style='color:black'><a href="http://www.eurekalert.org/pub_releases/2012-02/cwru-dqr020512.php">http://www.eurekalert.org/pub_releases/2012-02/cwru-dqr020512.php</a><o:p></o:p></span></p><p class=MsoPlainText><span style='color:black'><o:p> </o:p></span></p><p class=MsoPlainText>From the same article: <o:p></o:p></p><p class=MsoPlainText><o:p> </o:p></p><p class=MsoPlainText>Researchers are hoping for approval to study bexarotene in humans as soon as possible. Dr. Landreath related to the post that there is an urgency since he has heard from physicians that patients are already asking for this drug. He does note "We've got to work fast, and we have got to be right, we can't screw this up”.<o:p></o:p></p><p class=MsoPlainText><span style='color:black'><o:p> </o:p></span></p><p class=MsoPlainText><span style='color:black'>And from this article:<o:p></o:p></span></p><p class=MsoPlainText><span style='color:black'><o:p> </o:p></span></p><p class=MsoPlainText><span style='color:black'><a href="http://topnews.us/content/246219-skin-cancer-drug-bexarotene-reverses-alzheimers-mice">http://topnews.us/content/246219-skin-cancer-drug-bexarotene-reverses-alzheimers-mice</a><o:p></o:p></span></p><p class=MsoPlainText><span style='color:black'><o:p> </o:p></span></p><p class=MsoPlainText><span style='color:black'>this delightful comment!:<o:p></o:p></span></p><p class=MsoPlainText><span style='color:black'><o:p> </o:p></span></p><p class=MsoNormal><span style='color:black'>Noting that that within hours of being given the drug, the destructive brain plaque which was causing Alzheimer's in the mice started disappearing, lead researcher Gary Landreth told AFP: “We were shocked and amazed. Things like this had never, ever been seen before.”<o:p></o:p></span></p><p class=MsoPlainText><span style='color:black'><o:p> </o:p></span></p><p class=MsoPlainText><span style='color:black'>Ooooh, I like those words, purr them to me baby, NEVER EVER been seen before.<o:p></o:p></span></p><p class=MsoPlainText><span style='color:black'><o:p> </o:p></span></p><p class=MsoPlainText>>...One other thing, I recommend calling some large drug retailer and<o:p></o:p></p><p class=MsoPlainText>inquiring about Targretin sales. Are they spiking (no pun intended)?<o:p></o:p></p><p class=MsoPlainText><span style='color:black'><o:p> </o:p></span></p><p class=MsoPlainText><span style='color:black'>Good question. Eisai Corp's stock didn't spike way up, but the privately owned company Banner Pharmacaps, which applied for the fast track last October is sitting pretty. Note there are other medications which contain bexarotene besides Targretin. That one is promising because it is an oral. <o:p></o:p></span></p><p class=MsoPlainText><span style='color:black'><o:p> </o:p></span></p><p class=MsoPlainText><span style='color:black'>One possible scenario worries me: some lab tech from Case Western U buys a bunch of shares of Eisai, breakes into the lab in the middle of the night, switches the Alzheimer's mice with younger ones (seen one lab mouse ya seen em all) next day the researchers come in, run the tests, mice are suddenly smarter, the lab tech cashes out, flees into the night. Then tech sells short, reveals the trick, stocks drop, she cashes out a second time.<o:p></o:p></span></p><p class=MsoPlainText><span style='color:black'><o:p> </o:p></span></p><p class=MsoPlainText><span style='color:black'>Note Dr. Landreth's comment above: he did say "...within hours of being given the drug..." which counter indicates a sneaky lab technician in the middle of the night. Actually with that comment there should be preliminary results: we have hospitals which have cancer patients taking Targretin, and you know damn well someone somewhere would have suggested giving the caplets to the Alz patients by now.<o:p></o:p></span></p><p class=MsoPlainText><span style='color:black'><o:p> </o:p></span></p><p class=MsoPlainText><span style='color:black'>spike <o:p></o:p></span></p><p class=MsoPlainText><o:p> </o:p></p></div></body></html>